AlloVir, Inc.

NASDAQ:ALVR

0.75 (USD) • At close September 13, 2024
Bedrijfsnaam AlloVir, Inc.
Symbool ALVR
Munteenheid USD
Prijs 0.752
Beurswaarde 86,777,553
Dividendpercentage 0%
52-weken bereik 0.58 - 2.71
Industrie Biotechnology
Sector Healthcare
CEO Dr. Diana M. Brainard M.D.
Website https://www.allovir.com

An error occurred while fetching data.

Over AlloVir, Inc.

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus

Vergelijkbare Aandelen

Lexicon Pharmaceuticals, Inc. logo

Lexicon Pharmaceuticals, Inc.

LXRX

1.7 USD

Dyne Therapeutics, Inc. logo

Dyne Therapeutics, Inc.

DYN

34.06 USD

4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc.

FDMT

16.25 USD

ClearPoint Neuro, Inc. logo

ClearPoint Neuro, Inc.

CLPT

12.59 USD

Ocular Therapeutix, Inc. logo

Ocular Therapeutix, Inc.

OCUL

9 USD

Theratechnologies Inc. logo

Theratechnologies Inc.

THTX

1.35 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)